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Naltrexone and Bupropion Combination: A New Promising Therapy for
Long Term Weight Loss
Abstract
Background: Being overweight or obese is a growing health concern not just in the United States, but
worldwide. In 2009-2010, 2 out of 3 adults are considered overweight or obese, and 1 out of 3 adults are
considered obese in the U.S. Overweight and obesity acts as a major risk in cardiovascular diseases, diabetes,
cancer, and arthritis, and carries an overwhelming economic burden. With a 5-10% weight loss, patients can
benefit from reduced metabolic and cardiovascular risks; however, this is a challenging goal to achieve and
maintain. Naltrexone is a medication commonly used for opioid addiction and alcohol dependence, and
bupropion is commonly used for depression. Separately, these two medications have been shown to reduce
weight weakly; this review aims to evaluate the benefits of naltrexone and bupropion used in combination for
weight loss.
Method: An exhaustive literature search using the search engines Medline-OVID, CINAHL, and Web of
Science combining keywords naltrexone, bupropion, and weight loss was conducted. Eligible criteria include
research with naltrexone and bupropion combination therapy comparing to mono-therapy, other weight loss
therapy, or placebo. Only randomized controlled trials (RTC) were selected for maximum validity. Excluded
from this analysis were articles with animal subjects or other languages except English. Selected articles were
assessed for quality using the Grading of Recommendations, Assessment, Development and Evaluation
(GRADE).
Results: Three articles met the criteria and were included in this systematic review. In Greenway et al,
enrolled were 419 participants in this randomized, placebo and monotherapy controlled, double blind trial. In
general, at week 24, participants in most combination drug groups showed statistically significant weight loss
compared to monotherapy and placebo. In the COR-I study, 1742 participants enrolled in this randomized,
double blind, placebo controlled phase 3 trial. At week 56, mean change in body weight was statistically
significant in combination drug groups compared to placebo. In the COR-II study, a randomized, double
blind, placebo controlled study of 1,496 participants, the combination drug group achieved and maintained
weight loss at a more pronounced rate than placebo group at the completion of the 28 week trial.
Conclusion: Naltrexone and bupropion combination therapy shows promising evidence as a drug therapy for
long-term weight loss as evidenced by these studies. While this combination therapy is a safe alternative,
further research is needed to assess naltrexone and bupropion combination therapy against other current FDA
approved weight loss therapy and its effects on patients with complicated obesity.
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ABSTRACT 
 
Background: Being overweight or obese is a growing health concern not just in the United 
States, but worldwide. In 2009-2010, 2 out of 3 adults are considered overweight or obese, 
and 1 out of 3 adults are considered obese in the U.S.  Overweight and obesity acts as a 
major risk in cardiovascular diseases, diabetes, cancer, and arthritis, and carries an 
overwhelming economic burden. With a 5-10% weight loss, patients can benefit from 
reduced metabolic and cardiovascular risks; however, this is a challenging goal to achieve 
and maintain. Naltrexone is a medication commonly used for opioid addiction and alcohol 
dependence, and bupropion is commonly used for depression. Separately, these two 
medications have been shown to reduce weight weakly; this review aims to evaluate the 
benefits of naltrexone and bupropion used in combination for weight loss.    
 
Method: An exhaustive literature search using the search engines Medline-OVID, CINAHL, 
and Web of Science combining keywords naltrexone, bupropion, and weight loss was 
conducted. Eligible criteria include research with naltrexone and bupropion combination 
therapy comparing to mono-therapy, other weight loss therapy, or placebo. Only 
randomized controlled trials (RTC) were selected for maximum validity. Excluded from this 
analysis were articles with animal subjects or other languages except English. Selected 
articles were assessed for quality using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE).  
 
Results: Three articles met the criteria and were included in this systematic review. In 
Greenway et al, enrolled were 419 participants in this randomized, placebo and 
monotherapy controlled, double blind trial. In general, at week 24, participants in most 
combination drug groups showed statistically significant weight loss compared to 
monotherapy and placebo. In the COR-I study, 1742 participants enrolled in this 
randomized, double blind, placebo controlled phase 3 trial. At week 56, mean change in 
body weight was statistically significant in combination drug groups compared to placebo. 
In the COR-II study, a randomized, double blind, placebo controlled study of 1,496 
participants, the combination drug group achieved and maintained weight loss at a more 
pronounced rate than placebo group at the completion of the 28 week trial. 
 
Conclusion: Naltrexone and bupropion combination therapy is a promising new drug 
therapy for long-term weight loss with tolerable side effects.  
 
Keywords: naltrexone, bupropion, weight loss  
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Naltrexone and Bupropion Combination: A New Promising Therapy 
for Long Term Weight Loss 
BACKGROUND 
Being overweight is defined as a body mass index (BMI) of 25.0-29.9, and being 
obese is defined as 30.0 and above. This is a worldwide concern as its prevalence is rising, 
and it is a known risk factor that leads to increase morbidity and mortality. Statistics from 
2009-2010 National Center for Health Statistics indicate that 2 out of 3 adults are 
considered overweight or obese, and 1 out of 3 adults are considered obese, which is an 
increase since the last decades. 1  More importantly, overweight and obesity is associated 
with significant health risks such as diabetes, hypertension, high cholesterol, stroke, heart 
disease, certain cancers, and arthritis. 1  Due to its associations with chronic health diseases, 
overweight and obesity is a great economic burden. Obesity is accountable for the 
substantial amount of $345.9 million annually. 2   
Causes of overweight and obesity are many, relating to the environment, genetic 
makeup, metabolism, lifestyle behavior, and many more. Nonetheless, lifestyle modification 
is the first line treatment for obesity and overweight due to its low cost and low risk profile; 
however, this method is often ineffective due to low compliance rates and patients often 
need more than one intervention to reach and maintain a healthier weight. Adjunct to 
lifestyle modifications are medications that can be used long-term; these include orlistat, 
lorcaserin, and phentermine-topiramate combination. Orlistat is an inhibitor of pancreatic 
and intestinal lipases, which prevents the breakdown of ingested triglycerides into 
absorbable fatty acids and monoacylglycerol and reduces the absorption of fat. 3  Locaserin, 
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is a 2C serotonin receptor activated in the hypothalamus to reduce food intake. 4  Lastly, 
phentermine acts to reduce appetite through increasing norepinephrine in the 
hypothalamus, while topiramate affect gama-aminobutyric acid (GABA) receptors, which 
induce appetite-reducing mechanism that is not thoroughly understood. 4  While these 
drugs have been shown to be effective, some of its side effects are intolerable.  For 
example, orlistat may cause stomach pain, has diarrhea, leakage of oily stools;  locaserin 
may trigger headaches, dizziness, constipation, and cannot be taken with selective 
serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitor (MAOI); lastly 
phentermine-topiramate may cause tingling of hands and feet, dizziness, taste alterations, 
insomnia, and may lead to birth defects.  
Recently, the Food and Drug Administration (FDA) approved another weight loss 
medication, naltrexone/bupropion (NB) combination, also marketed with brand name 
Contrave. NB individually has been in the market for over 20 years. Naltrexone is an opioid 
receptor antagonist marketed in the U.S. for the treatment of narcotic and alcohol 
dependency, while bupropion is a dopamine and norepinephrine reuptake inhibitor 
prescribed as an antidepressant and smoking cessation aid. 5  Separately, these two drugs 
are weak weight loss interventions; however, together they have synergistic effects in the 
CNS that reduce food intake by stimulation of pro-opiomelanocortin (POMC) neuronal firing 
and modulate food cravings through an effect on the mesolimbic reward pathways at the 
same time. 5,6  Research on central nervous system (CNS) pathways that regulate food 
intake and bodyweight has identified the hypothalamic melanocortin system and the 
mesolimbic reward system as the two main key systems. The hypothalamic melanocortin 
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system integrates input related to energy balance and produces anorexigenic signaling 
while the mesolimbic modulates reward value and goal-oriented behavior. 7  NB was 
thought to play in important role into these complex systems, which makes this drug a 
promising means for weight loss. Moreover, naltrexone  and bupropion has been used by 
providers for over 20 years, and their ADRs profiles are typically mild, which also make is 
drug a valuable drug loss regimen as it gives providers more prescribing powers and 
patients more conservative options for weight loss. This review aims to evaluate the 
benefits of NB in treating patients who are overweigh or obese.  
METHODS 
An exhaustive literature search using the search engines Medline-OVID, CINAHL, and 
Web of Science combining keywords naltrexone, bupropion, and weight loss was 
conducted. Eligible criteria include research with naltrexone and bupropion combination 
therapy comparing to mono-therapy, other weight loss therapy, or placebo. Only 
randomized controlled trials (RTC) were selected for maximum precision. Excluded from this 
analysis were articles without randomization, animal subjects, and other languages except 
English. Articles were scanned for relevance and its attached references were also further 
scanned for related researches. Finally, the selected articles were assessed for quality using 
the Grading of Recommendations, Assessment, Development and Evaluation (GRADE). 
RESULTS 
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Initial search combining all 3 key terms yield 17, 13, and 54 in Medline-OVID, 
CINAHL, and Web of Science respectively. After screening the articles according to the 
eligible criteria, 3 articles 6-8  met the requirements for this systematic review. See Table I. 
Greenway et al 2009 
This randomized, placebo and mono-therapy controlled, double blind, dose finding 
trial 8  took place between August 2005 and December 2006 in seven U.S. outpatient clinics. 
Included were 419 participants with uncomplicated obesity, defined as BMI 30-40kg/m2, 
nonsmokers, 18-60 years old, normotensive, low density lipoprotein (LDL) <190mg/dl, 
triglyceride < 400mg/dl, fasting glucose < 140 mg/dl, no significant abnormalities on 
complete blood count, urinalysis, or thyroid stimulating hormone (TSH), and scored lower 
than 11 on their the depression or anxiety components of the Hospital Anxiety and 
Depression Scale (HADS). 8   
Subjects were randomized by site and gender. All seven sites, subjects, and the 
study team were blinded to the study drug throughout except in emergency situations. The 
study was carried out with two cohorts. In cohort 1, participants were randomized into five 
groups in a 1:1:1:1:1 ratio: bupropion SR 400mg/d plus naltrexone IR 48mg/d (NB48); 
bupropion SR 400mg/d plus naltrexone 16mg/d (NB16); bupropion SR 400mg/d plus 
naltrexone placebo (Bup); naltrexone IR 48mg/d plus bupropion placebo (nal48); bupropion 
placebo plus naltrexone placebo (placebo). In cohort 2, participants were randomized in a 
1:3 ratio: bupropion placebo and naltrexone placebo (placebo); bupropion SR 400mg/d plus 
naltrexone IR 32mg/d (NB32). Drugs were gradually titrated up weekly and reached 
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maximum dose at week 4. All groups were prognostically balanced at the start of the trial; 
however, there was a female and Caucasian dominance. 8  
In addition, participants were advised to follow a hypo-caloric diet of 500kcal below 
maintenance diet plus 30 min walking exercise most days of week. Subjects were evaluated 
at screening, baseline, and every 4 weeks through week 48. Primary endpoint was 
difference in body weight. Secondary endpoint was absolute change in body weight, waist 
circumference, triglycerides, glues, insulin, high-density lipoprotein (HDL), low-density 
lipoprotein (LDL), total cholesterol, blood pressure, and pulse. Exploratory endpoints 
include food craving (assessed by the Yale Brown Obsessive Compulsive Scale). 8  
At 24 week, placebo subtracted weight loss in the intent to treat population (ITT) 
was -4.62kg for NB16 (95% CI, -6.24 to -2.99, p<0.001), -4.65kg for NB32 (95% CI, -6.20 to – 
3.09, p<0.001), and -3.53kg for NB48 (95% CI, -5.19 to -1.90, p<0.001). At 48 weeks, 
placebo-subtracted weight loss was -6.45kg (95% CI, -8.46 to -4.43, P < 0.001) for NB16, -
5.92kg (95% CI, -7.82 to -4.02, P < 0.001) for NB32, and -6.39kg (95% CI, -8.69 to -4.09, P < 
0.001) for NB48. Weight loss was significant in NB combinations compared to monotherapy 
except with NB48 (p = 0.0684). A greater than 10% Weight loss was 4.89 times more likely in 
the NB combination groups compared to placebo and monotherapy. This comparison also 
resulted in a number needed to treat (NNT) of 8 (see Table II). However, there is some loss 
of significance when looking at the NB48 group. Weight loss continued after 24 weeks, and 
the study was stopped as planned at 48 weeks. Researchers also found that NB32 was 
associated with improvements in cardiometabolic markers (waist circumference, fasting 
insulin, fasting glucose, triglycerides, HDL cholesterol, LDL cholesterol, total cholesterol, 
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systolic blood pressure (SBP), and diastolic blood pressure (DBP) compare to other doses, 
monotherapy, and placebo. The Yale Brown Obsessive and Compulsive Assessment II scores 
between study baseline and completion showed no significant difference in NB combination 
drugs, monotherapy, or placebo. 8   
The COR-I Study 
This randomized, double blind, placebo controlled, phase 3 trial took place at 34 
health centers in the U.S. from October 2007 to May 2009. Participants included 260 men 
and 1,742 women aged 18-65 years with BMI of 30-45kg/m2 and uncomplicated obesity, or 
BMI of 27-45kg/m2 and controlled hypertension or dyslipidemia, or both. Excluded from 
study were patients who were pregnant or lactating, obese with known endocrine origin, 
type 1 or type 2 diabetes; cerebrovascular, hepatic, or renal disease; previous surgical or 
device intervention for obesity; loss or gain of more than 4 kg within 3 months before 
randomization; severe psychiatric illness; history of seizures; treatment with bupropion or 
naltrexone in the previous 12 months; history for alcohol or drug abuse in previous 12 
months. Participants were randomized into a 1:1:1 ratio of: naltrexone SR 32mg/day plus 
bupropion SR 360mg/day (NB32); naltrexone SR 16 mg/day plus bupropion SR 360mg/day 
(NB16); or placebo. All groups were prognostically balanced at the start of the trial; 
however, there was a female and Caucasian dominance. Beginning with a quarter of the full 
dose, each drug was titrated up weekly and reached full dose at week 4. Patients were also 
advised of a mild hypocaloric diet consisting of 500kcal deficit per day based on WHO 
algorithm for calculating resting metabolic rate and were advised of lifestyle modification at 
baseline and at 12, 24, 36, and 48 weeks. All subjects were evaluated at screening and every 
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4 weeks for 56 weeks total. Drug compliance was assessed during evaluation by pill count. 
Patients were considered non-compliant if they were found to take medications correctly 
<70% of the time and were re-educated. Furthermore, non-compliant patients with two 
consecutive visits or 15 consecutive days were re-evaluated for continuation. 7    
As a result, 870 (50%) participants completed 56 weeks of treatment. Rates of 
discontinuation were similar across all 3 subgroups. Primary endpoints were change in body 
weight and proportions of participants with decrease of 5% or more from baseline at end of 
study. Mean change in body weight was -1.3% in placebo, -5.0% in NB16, and -6.1% in NB32 
group. 16% of participants had decrease in bodyweight of 5% or more in placebo, compared 
to 39% in NB16, and 48% in NB32 (Table 1). Weight loss was statistically significant in both 
NB32 and NB16 groups compared to placebo, with NB32 with the greatest success in losing 
bodyweight compared to other 2 subgroups. For example, participants in NB32 groups were 
2.66 times more likely to experience ≥5% weight loss compared to placebo, 3.01 times more 
likely to experience ≥10% weight loss compared to placebo, 5.26 times more likely 
experience ≥15% weight loss compared to placebo (see Table II). Weight loss was observed 
as soon as week 4, with peak weight loss between week 28 and 36. Secondary endpoint 
include proportion of participants with ≥10% and ≥15%, change in cardiometabolic risk 
factors, patient reported measures of appetite, control of eating and food craving, 
depressive symptoms, and weight-related quality of life. As a result, participants on NB32 
and NB16 also showed significant improvements from baseline to 56 weeks in waist 
circumference, insulin resistance, and concentrations of HDL cholesterol, triglycerides, high-
sensitivity C-reactive protein, and fasting glucose compared to placebo. Control of Eating 
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Questionnaire (COEQ), a proven reliable method which measure cravings for specific food 
items shows combined naltrexone and bupropion reduced hunger or desire for sweet, non-
sweet, or starchy foods; increased feeling of fullness, reduced incidence and strength of 
food cravings; reduced eating in response to food cravings; and increased ability to resist 
food cravings and control eating. 7  
The COR-II Study  
This randomized, parallel-arm, double-blind, placebo controlled, phase 3 trial was 
performed in 36 U.S. private or institutional practices between December 2007 and June 
2009 for 56 weeks. Participants included 229 men and 1267 women age 18-65 years old 
with BMI 30-45kg/m2, or BMI 27- 45kg/m2 and controlled hypertension and or 
dyslipidemia. Excluded were patients with diabetes; significant vascular, hepatic, or renal 
disease; weight change of more than 4 kg within 3 months prior to randomization; history 
of seizures or serious psychiatric illness. Participants were randomized via interactive voice 
system in a 2:1 ratio. Patients either received SR Naltrexone 32mg/day plus SR Bupropion 
360mg/day (NB32), or SR Naltrexone 16mg/day plus SR Bupropion 360mg/day (NB16), or 
matching placebo. All groups were prognostically balanced at the start of the trial; however, 
there was a female and Caucasian dominance. Naltrexone and bupropion was titrated up 
weekly and reached full dose at week 5. Furthermore, participants in NB32 group with less 
than 5% weight loss at week 28 were re-randomized, double-blinded to receive either NB32 
or NB48 in 1:1 ratio for the remaining of the study. Patients were evaluated at baseline and 
every 4 weeks. At baseline, 12, 24, 36, and 48 weeks, patients also received instructions to 
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follow a 500kcal/day deficit hypocaloric diet, increase physical activity, and behavioral 
modification. 6  
The study concluded with 54% completion rate at week 56, with drop out rates 
similar across study groups. Primary endpoint was percent change in weight and the 
proportion of participants with ≥5% in weight loss and week 28. 6  As a result, weight loss 
was most statistically significant with NB32 compared to placebo at week 28 and continues 
to progress through week 56. Participants on NB32 lost 6.5% of bodyweight compare to 
1.9% of participants on placebo (p-value <0.001). Participants on NB32 also lost more body 
weight (-6.4%) compared placebo (-1.2%) at week 56 (p-value <0.001), exemplifying that 
NB32 is superior to placebo at maintaining weight loss. Risk ratio for NB32 vs placebo at 
completion of study were 2.96, 1.66, and 5.61 for ≥5%, 10%, and 15% respectively, 
exemplifying that patients taking combination drug NB32 were almost two times or more 
likely to lose weight (see Table II).  Secondary endpoints included participants with ≥10% 
and ≥15% weight loss, improvements in cardiometabolic parameters such as waist 
circumference, triglycerides, HDL cholesterol, LDL cholesterol. 6   
Other endpoints were high sensitive C-reactive protein (hsCRP), fasting blood 
glucose, fasting insulin, homeostatis model assessment of insulin resistance (HOMA-IR), 
impact of Weight on Quality of Life (IWQOL, quality physical function, self-esteem, and 
sexual life subscales), Control of Eating Questionnaire (COEQ, indicates control of eating, 
food craving, frequency of craving, and difficulty in resisting food cravings), systolic blood 
pressure (SBP), diastolic blood pressure (DBP), and Inventory of Depressive 
Symptomatology (IDS-SR). Compared to placebo, NB32 participants showed improved 
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hsCRP, fasting blood glucose, fasting insulin, insulin resistance, and quality of life. 
Participants also had reduced food craving, reduced frequency of craving, reduced difficulty 
in resisting food cravings, and improved control of eating. 6   
Patients on NB32 showed a slight increase in both SBP and DBP compared to 
placebo; however, the changes were not statistically significant as the mean SBP and DBP 
remain within approximately 1mmHg of baseline. 6  Lastly, IDS-SR questionnaire (score 
range from 0-84, a total score of ≤13 suggests no depression) shows no significant changes 
in depression comparing NB32 with placebo.  
DISCUSSION 
The three studies 6-8  listed above were dissected and consistently shows that 
combination of naltrexone and bupropion leads to improvement in weight loss, 
cardiometabolic risk factors, and control in eating habits. First, the Greenway et al 8  study 
shows that weight loss was most significant in participants in the NB16 and NB 32 group 
compared to other interventions and weight loss was sustained over 48 weeks; participants 
in this subject group lost at least 5% body weight loss compared to placebo and Nal48 
(naltrexone-bupropion placebo). See Table II. Adverse effects are consistent with the effects 
of naltrexone and bupropion profile, with the most common side effects being nausea, 
headache, dizziness, and insomnia. In addition, NB 32 was associated with statistically 
significant improvements in cardiometabolic risk factors. Second, in the COR-I study, 7  
participants were three times more likely to lose 5% to 10% of body weight in NB32 groups 
compared to placebo. Patients on NB32 also showed greater improvements in 
cardiometabloc risk factors and weight-related quality of life. With mild adverse drug 
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reactions of nausea, headache, constipation, dizziness, vomiting, and dry mouth, this drug 
shows favorable results as a means for long-term weight loss of obese or overweight adults. 
Last, in COR-II study, 6  participants in NB32 group were associated with most significant 
weight loss and great improvement in cardiometabolic markers compared to placebo. 
Weight loss was maintained in NB32 to completion of study at week 56. Furthermore, NB32 
participants were more likely than NB16 and placebo to achieve more than 5%, 10%, and 
15% weight loss. See Table II. The adverse drug reactions of naltrexone and bupropion 
seemed consistent with other trials5 and their known profile, with most common side 
effects being mild to moderate nausea, constipation, and headache.  
While all three studies 6-8  showed consistent results, the limitations of these studies 
could not be dismissed. First, there were risks of bias, variability across the studies, and 
important flaws in these studies. Sampling in all three studies consisted of mainly middle 
aged white females, which limits the generalizability of the results. Most selected 
participants were voluntary females, which implies that these women were more motivated 
to lose weight and were more likely to be compliant to the study drugs. Second, completion 
rates of these studies were low: 63% in the Greenway et al 8  study, 50% in the COR-I study, 7  
and 54% in the COR-II study. 6  Participants in the NB groups likely discontinued due to 
adverse reactions, whereas participants in placebo group discontinued due to 
unsatisfactory weight loss. Participants who left were even across all groups, and data were 
logistically equal; however, these low completion rates can risk attrition bias. Third, all three 
studies 6-8 excluded patients with complicated obesity, such as patients with cardiovascular 
disease or diabetes, which abandoned the purpose to find a drug that works for these 
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patients as obesity is an important risk factor. Fourth, two of these studies did not collect 
participants’ adherence to diet and exercise. These missing data are an important variance 
across patient groups. Fifth, none of the studies compared NB combined therapy with other 
current FDA approved weight loss therapy. Although data on naltrexone and bupropion 
combination drug for weight loss is promising, it fails to compare itself to other approved 
weight loss medications. This results in an overall moderate quality of evidence (see Table 
I). All in all, more studies is recommended to obtain a larger sample size, more male 
participants, participants with diabetes or cardiovascular disease, account for lifestyle 
modification more consistently, and comparison with other current weight loss 
medications.  
CONCLUSION 
Naltrexone/bupropion combined therapy has been demonstrated to be effective for 
long-term management of weight loss in overweight or obese adults. Furthermore, the 
effective dose of naltrexone and bupropion was also included in the study, with naltrexone 
SR 32mg/day and Bupropion SR 360-400mg/day as the most effective dose that is tolerable. 
Naltrexone and bupropion are medications that have been used for over 20 years and their 
adverse drug reaction profiles are familiar to primary care providers; therefore, providers 
are more likely to be comfortable to prescribe this medication. Most importantly, adverse 
drug reactions to naltrexone and bupropion are tolerable, which makes its benefits 
outweigh its risks. Further research is needed to assess naltrexone and bupropion combined 
therapy against other current FDA approved weight loss therapy and its effects on patients 
with complicated obesity. 
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Table I. Characteristics of Reviewed Studies 
Quality Assessment  
Importance  Downgrade Criteria 
Quality No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Weight loss >5% 
3 3 RCT No serious limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely Moderate Important 
Weight loss >10% 
3 3 RCT No serious limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely Moderate Important 
Weight loss >15% 
2 2 RCT No serious limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely Moderate Important 
Table II. Summary of Findings 
Study Percent of 
subjects with 
weight loss 
Number of 
participants (%) in 
NB groups 
Number of participants (%) in 
monotherapy/placebo groups  
RRa NNTa 
Greenway 
et al8  
Total in groupsb n=171 n=190   
≥5% 81 (48%) 32 (17%) 2.72 4 
≥10% 29 (17%) 7 (4%) 4.89 8 
The COR-I 
Trial7  
Total in groups b n=942 n=511   
≥5% 412 (44%) 84 (16%) 2.66 4 
≥10% 211 (22%) 38 (7%) 3.01 7 
≥15% 97 (10%) 10 (2%) 5.26 12 
The COR-II 
Trial6  
Total in week 28 
groups b n=825 n=456 
  
≥5% (week 28) 459 (56%) 80 (18%) 3.17 3 
≥10% (week 28) 225 (27%) 32 (7%) 3.89 5 
≥15% (week 28) 84 (10%) 8 (7%) 1.45 32 
Total in week 56 
groups b n=702 n=456 
  
≥5% (week 56) 355 (51%) 78 (17%) 2.96 3 
≥10% (week 56) 199 (28%) 26 (17%) 1.66 9 
≥15% (week 56) 95 (14%) 11 (2%) 5.61 9 
a RR and NNT were calculated by combining data from all of the NB combination groups and comparing it to combined data from the 
monotherapy and placebo groups. Greenway et al8 groups were placebo, Nal48, Bup, NB16, NB32, NB48; The COR-I trial7 groups were 
placebo, NB16, and NB32; and the COR-II trial6 groups were placebo and NB32. 
b Intention to treat analysis or primary analysis data used.  
 
